AboutContactsEditorial StaffEditorial CouncilArchiveFor AuthorsFor Reviewers

Why Nicorandil is not Considered to be the First-line Antianginal Drug

Journal «MEDICINA» ¹ 3, 2020, pp.25-47 (Reviews)

Authors

Bel'diev S. N.
MD, PhD, Associate Professor, Chair for Therapy and Cardiology1

Andreeva E. V.
MD, PhD, Associate Professor, Chair for Therapy and Cardiology1

Berezina E. I.
MD, PhD, Associate Professor, Chair for Therapy and Cardiology1

Egorova I. V.
MD, PhD, Associate Professor, Chair for Therapy and Cardiology1

Medvedeva I. V.
MD, PhD, Associate Professor, Chair for Therapy and Cardiology1

Platonov D. Yu.
MD, PhD, MPH, Head, Chair for Therapy and Cardiology1

1 - Tver State Medical University, Tver, Russia

Corresponding Author

Bel'diev Sergej; e-mail: sbeldiev@yandex.ru

Conflict of interest

Authors have no conflict of interest.

Funding

The study had no sponsorship.

Abstract

According to the results of several short-term randomized controlled trials (RCTs), nicorandil is not inferior in its antianginal efficacy to beta-blockers (BB), calcium channel blockers (CCB) and long-acting nitrates (LAN). At the same time, in some short-term RCTs, as well as in the long-term RCT IONA (2002), it was shown that antianginal efficacy of nicorandil as monotherapy or in combination with other antianginal drugs did not differ from placebo. Ability of nicorandil to reduce the risk of adverse cardiovascular events, demonstrated in the RCT IONA, requires confirmation in a long-term trial with a stronger primary endpoint and concomitant treatment that would meet the current guidelines for the management of patients with chronic coronary syndromes. In this regard, and also taking into account the proven ability of nicorandil to cause gastrointestinal ulcerations, European experts currently consider nicorandil as a drug that is inferior in priority of choice to the first-line antianginal drugs (BB, CCB) and, in some cases, to the second-line drugs (LAN, ivabradine, ranolazine, trimetazidine).

Key words

nicorandil, stable angina, efficacy, safety

DOI

References

1. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407-477. doi: 10.1093/eurheartj/ehz425.

2. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949-3003. doi: 10.1093/eurheartj/eht296.

3. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359(9314): 1269-75. doi: 10.1016/s1062-1458(02)00678-5.

4. Malysheva A.M., Martsevich S.Yu., Ginzburg M.L. Primenenie nikorandila – preparata s dopolnitel'nymi kardioprotektivnymi svojstvami – u pacientov s ishemicheskoj bolezn'ju serdca [Cardioprotective drug nicorandil in coronary heart disease]. Terapevticheskij arhiv [Therapeutic Archive] 2011; 83(9): 14-19. (In Russ.).

5. Belousov Yu.B. Primenenie nikorandila pri serdechno-sosudistyh zabolevanijah i optimizacija shem ego naznachenija [The use of nicorandil in cardiovascular diseases and the optimization of schemes of its administration]. Arhiv vnutrennej mediciny [The Russian Archives of Internal Medicine] 2012; (1): 46-52. doi: 10.20514/2226-6704-2012-0-1-46-52. (In Russ.).

6. Lupanov V.P. Sovremennoe medikamentoznoe lechenie stabil'noj ishemicheskoj bolezni serdca (novye amerikanskie rekomendacii po diagnostike i lecheniju stabil'noj ishemicheskoj bolezni serdca, 2012 g.) [Modern drug treatment of stable ischemic heart disease (new American guideline for the diagnosis and treatment of stable ischemic heart disease, 2012)]. RMZh [Russian Medical Journal] 2013; 21(4): 170-174. (In Russ.).

7. Nifontov E.M., Andreev Ja.V. Primenenie otkryvatelja ATF-zavisimyh kalievyh kanalov nikorandila dlja lechenija ishemicheskoj bolezni serdca [The application of ATP-sensitive potassium channels' opener nicorandil in treatment of coronary heart disease]. Rossijskij semejnyj vrach [Russian Family Doctor] 2014; 18(3): 18-22. (In Russ.).

8. Sizova Zh.M., Kozlova N.V., Zakharova V.L., Shameeva E.S. Sravnitel'naja ocenka vlijanija izosorbida dinitrata, izosorbida-5-mononitrata i nikorandila na chastotu pristupov stenokardii i vazoregulirujushhuju funkciju jendotelija u bol'nyh ishemicheskoj bolezn'ju serdca [Comparative assessment of effects of isosorbide dinitrate, isosorbide-5-mononitrate and nicorandil on the frequency of angina attacks and vasoregulating endothelial function in patients with ischemic disease hearts]. Kardiologija [Cardiology] 2015; 55(2): 10-15. (In Russ.).

9. Karpov Yu.A., Kukharchuk V.V., Lyakishev A.A., Lupanov V.P., Panchenko E.P., Komarov A.L., et al. Diagnostika i lechenie hronicheskoj ishemicheskoj bolezni serdca [Diagnosis and treatment of chronic ischemic heart disease]. Kardiologicheskij vestnik [Cardiological Bulletin] 2015; 10(3): 3-33. (In Russ.).

10. Bubnova M.G., Barbarash O.L., Doletsky A.A., Krasnitsky V.B., Lebedev E.V., Lyamina N.P., et al. Ostryj infarkt miokarda s pod#emom segmenta ST jelektrokardiogrammy: reabilitacija i vtorichnaja profilaktika [Acute ST elevation myocardial infarction: aftercare and secondary prevention]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2015; (1): 6-52. doi: 10.15829/1560-4071-2015-1-6-52. (In Russ.).

11. Ryabikhin E.A., Mozheiko M.E., Krasilnikova Yu.A. Ocenka vlijanija terapii nikorandilom na pokazateli kachestva zhizni i prognoza u bol'nyh stabil'noj stenokardiej [Assessment of the impact of nicorandil on the quality of life and prognosis indicators in patients with stable angina]. Kardiologija [Cardiology] 2016; 56(11): 12-17. doi: 10.18565/cardio.2016.11.12-17. (In Russ.).

12. Mazur N.A. Optimal'naja medikamentoznaja terapija bol'nyh so stenokardiej i ee vlijanie na smertnost' [Optimal drug therapy for patients with angina and its impact on mortality]. Consilium Medicum 2017; 19(1): 30-35. (In Russ.).

13. Vertkin A.L., Knorring G.Yu. Za ramkami invazivnoj kardiologii [Beyond the scope of invasive cardiology]. Poliklinika [Polyclinic] 2018; (5): 49-54. (In Russ.).

14. Hanai Y., Mita M., Hishinuma S., Shoji M. Sistematicheskij obzor i metaanaliz jeffektivnosti i bezopasnosti nikorandila pri neprodolzhitel'nom lechenii stabil'noj stenokardii v sravnenii s β-adrenoblokatorami, nitratami prolongirovannogo dejstvija i blokatorami medlennyh kal'cievyh kanalov [Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists]. Vrach [The Doctor] 2019; 30(2): 60-67. (In Russ.).

15. Sravnitel'nyj analiz jeffektivnosti i bezopasnosti nikorandila pri lechenii pacientov so stabil'noj stenokardiej v sravnenii s terapiej β-adrenoblokatorami, nitratami prolongirovannogo dejstvija i blokatorami medlennyh kal'cievyh kanalov (referat) [Comparative analysis of nicorandil efficacy and safety in the treatment for patients with stable angina in comparison with therapy with β-blockers, long-acting nitrates, and slow calcium channels blockers (report)]. RMZh. Medicinskoe obozrenie [Russian Medical Journal. Medical Review] 2019; 3(6): 24-30. (In Russ.)

16. Meany T.B., Richardson P., Camm A.J., Coltart J., Griffith M., Maltz M.B., et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989; 63(21): 66J-70J. doi: 10.1016/0002-9149(89)90208-7.

17. Hughes L.O., Rose E.L., Lahiri A., Raftery E.B. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990; 66(7): 679-682. doi: 10.1016/0002-9149(90)91129-t.

18. Meeter K., Kelder J.C., Tijssen J.G., Bucx J.J., Henneman J.A., Kerker J.P., et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992; 20(Suppl 3): S59-S66. PMID: 1282178.

19. Di Somma S., Liguori V., Petitto M., Carotenuto A., Bokor D., de Divitiis O., et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993; 7(1): 119-123. doi: 10.1007/BF00878320.

20. Ulvenstam G., Diderholm E., Frithz G., Gudbrandsson T., Hedbäck B., Höglund C., et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992; 20(Suppl 3): S67-S73. doi: 10.1097/00005344-199206203-00012.

21. Guermonprez J.L., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993; 14(Suppl B): 30-34. doi: 10.1093/eurheartj/14.suppl­_b.30.

22. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992; 20(Suppl 3): S74-S81. doi: 10.1097/00005344-199206203-00013.

23. Thadani U., Strauss W., Glasser S.P., Frishman W., Burger A.J., Locker P.K., et al. Evaluation of antianginal and anti-ischemic efficacy of nicorandil: results of a multicenter study. Abstracts of original contributions: 43rd Annual Scientific Session. J Am Coll Cardiol 1994; 23(2 Suppl 1): 276A. doi: 10.1016/S0735-1097(10)80315-8.

24. Gilyarevskiy S.R., Rezvan V.V., Kuz'mina I.M., Golshmid M.V. The role of alternative approaches to anti-ischemic therapy in patients with stable course of ischemic heart disease. Kardiologiia [Cardiology] 2013; (11): 84-89. (In Russ.).

25. Gilyarevskiy S.R., Rezvan V.V., Kuz'mina I.M., Golshmid M.V. Sovremennye podhody k protivoishemicheskoj terapii u bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdca [The modern approaches to anti-ischemic therapy in patients with stable course of ischemic heart disease]. Medicinskij alfavit [Medical Alphabet] 2013; 2(21): 15-20. (In Russ.).

26. Goldschmidt M., Landzberg B.R., Frishman W.H. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. J Clin Pharmacol 1996; 36(7): 559-572. doi: 10.1002/j.1552-4604.1996.tb04219.x.

27. Rajaratnam R., Brieger D.B., Hawkins R., Freedman S.B. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 1999; 83(7): 1120-1124. doi: 10.1016/s0002-9149(99)00025-9.

28. Thadani U. Can nicorandil treat angina pectoris effectively? Nat Clin Pract Cardiovasc Med 2005; 2(4): 186-187. doi: 10.1038/ncpcardio0159.

29. Chaitman B.R, Sano J. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. Clin Cardiol 2007; 30(2 Suppl I): I25-I30. doi: 10.1002/clc.20050.

30. Rousan T.A., Mathew S.T, Thadani U. Drug therapy for stable angina pectoris. Drugs 2017; 77(3): 265-284. doi: 10.1007/s40265-017-0691-7.

31. Rousan T.A., Thadani U. Stable angina medical therapy management guidelines: A critical review of guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. Eur Cardiol 2019; 14(1): 18-22. doi: 10.15420/ecr.2018.26.1.

32. Simpson D., Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 2004; 64(17): 1941-1955. doi: 10.2165/00003495-200464170-00012.

33. Manolis A.J., Poulimenos L.E., Ambrosio G., Kallistratos M.S., Lopez-Sendon J., Dechend R., et al. Medical treatment of stable angina: a tailored therapeutic approach. Int J Cardiol 2016; 220: 445-453. doi: 10.1016/j.ijcard.2016.06.150.

34. Tarkin J.M., Kaski J.C. Nicorandil and long-acting nitrates: vasodilator therapies for the management of chronic stable angina pectoris. Eur Cardiol 2018; 13(1): 23-28. doi: 10.15420/ecr.2018.9.2.

35. Fox K., Garcia M.A., Ardissino D., Buszman P., Camici P.G., Crea F., et al. Guidelines on the management of stable angina pectoris: full text. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. 2006. Available at: https://www.escardio.org/static-file/Escardio/Press-media/press-releases/2006/guidelines­_Angina­_FT­_2006.pdf. Accessed: 09/30/2020.

36. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126(25): e354-e471. doi: 10.1161/CIR.0b013e318277d6a0.

37. Fala L. Corlanor (Ivabradine), First HCN channel blocker, FDA approved for the treatment of patients with heart failure. Am Health Drug Benefits 2016; 9(Spec Feature): 56-59. PMID: 27668045.

38. Bel'diev S.N., Egorova I.V., Gavrilenko N.G., Berezina E.I., Medvedeva I.V., Platonov D.Yu. Otrazhenie zarubezhnyh dannyh ob ul'cerogennom dejstvii nikorandila v otechestvennyh publikacijah 2009-2018 godov [The reflection of foreign data on nicorandil-induced ulcerations in Russian publications in 2009-2018 years]. Medicina [Medicine] 2019; 7(2): 40-58. doi: 10.29234/2308-9113-2019-7-2-40-58. (In Russ.).

39. Gilyarevskiy S.R., Orlov V.A., Kuz'mina I.M. Problema vybora optimal'noj lekarstvennoj terapii u bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdca [The problem of the optimal pharmacotherapy choice in patients with stable coronary artery disease]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2012; 8(3): 457-462. doi: 10.20996/1819-6446-2012-8-3-457-462. (In Russ.).

40. Mikhin V.P. Citoprotekcija v kardiologii: dostignutye uspehi i perspektivy. Chast' 2 [Cytoprotection in cardiology: successes and prospects. Part 2]. Arhiv vnutrennej mediciny [The Russian Archives of Internal Medicine] 2014; (2): 33-40. doi: 10.20514/2226-6704-2014-0-2-33-40. (In Russ.).

41. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu. Jeffektivnost', bezopasnost' i otdalennye ishody primenenija nikorandila u bol'nyh stabil'noj ishemicheskoj bolezn'ju serdca po dannym randomizirovannogo i nabljudatel'nogo issledovanij [Efficacy, safety and long-term outcomes of nicorandil use in patients with stable ischemic heart disease according to the results of randomized and observational studies]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2019; 15(5): 641-648. doi: 10.20996/1819-6446-2019-15-5-641-648. (In Russ.).

42. Belsey J., Savelieva I., Mugelli A., Camm A.J. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol 2015; 22(7): 837-848. doi: 10.1177/2047487314533217.

43. Karpov Yu.A. Antianginal'naja terapija: jevoljucija podhodov v novyh evropejskih rekomendacijah [Antianginal therapy: evolution of approaches in new European guidelines]. Atmosfera. Novosti kardiologii [Atmosphere. Cardiology News] 2019; (4): 39-48. doi: 10.24411/2076-4189-2019-12173. (In Russ.).

44. Martsevich S.Yu., Kutishenko N.P., Deev A.D. Sravnitel'naja ocenka antianginal'noj jeffektivnosti i bezopasnosti preparata nikorandil na fone bazisnoj terapii β-adrenoblokatorami u bol'nyh ishemicheskoj bolezn'ju serdca so stabil'noj stenokardiej [Comparative assessment of antianginal efficacy and safety of nicorandil at the background of therapy with β-adrenoblockers in ischemic heart disease patients with stable angina]. Kardiologija [Cardiology] 2016; 56(10): 30-34. doi: 10.18565/cardio.2016.10.30-34. (In Russ.).

45. Voronina V.P., Martsevich S.Yu., Kutishenko N.P., Deev A.D. Ocenka antiishemicheskogo i antianginal'nogo jeffektov nikorandila s pomoshh'ju nagruzochnyh testov na tredmile v ramkah issledovanija KVAZAR [Assessment of antiischemic and antianginal effects of nicorandil by treadmill test, under the framework of KVAZAR study]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2017; (3): 97-103. doi: 10.15829/1560-4071-2017-3-97-103. (In Russ.).

46. Martsevich  S.Yu., Lukina Y.V., Kutishenko N.P., Akimova À.V., Voronina V.P., Lerman Î.V., et al. Nabljudatel'noe mnogocentrovoe issledovanie primenenija nikorandila u bol'nyh stabil'noj ishemicheskoj bolezn'ju serdca s vysokim serdechno-sosudistym riskom (NIKEJa): dizajn, pervye rezul'taty [Observational multicenter trial of nicorandil use in stable coronary heart disease high risk patients (NIKEA): design and first results]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2017; (9): 75-82. doi: 10.15829/1560-4071-2017-9-75-82. (In Russ.).

47. Minushkina L. Antianginal'naja terapija bol'nyh so stabil'noj stenokardiej [Antianginal therapy in patients with stable angina]. Vrach [The Doctor] 2017; (5): 25-29. (In Russ.).

48. Potupchik T., Veselova O., Evert L., Averyanova O., Romanchikov A. Jeffektivnost' nikorandila v lechenii bol'nyh ishemicheskoj bolezn'ju serdca [Efficacy of nicorandil in the treatment of patients with coronary heart disease]. Vrach [The Doctor] 2017; (12): 23-27. (In Russ.).

49. Gostishchev R., Soboleva G., Samko A., Osiev A. Farmakologicheskoe prekondicionirovanie. V fokuse – nikorandil [Pharmacological preconditioning. Focus on nicorandil]. Vrach [The Doctor] 2018; (8): 75-81. (In Russ.).

50. Makarovskaya M.V., Ryazanov A.S., Kudryavtsev A.A., Kapitonov K.I. Vlijanie nikorandila na kachestvo zhizni i techenie zabolevanija u pacientov s serdechnoj nedostatochnost'ju pri ishemicheskoj bolezni serdca [Effect of nicorandil on the quality of life and course of the disease in patients with heart failure in ischemic heart disease]. Consilium Medicum 2018; 20(10): 47-52. doi: 10.26442/2075-1753­_2018.10.47-52. (In Russ.).

51. Ramrakha P., Hill J. Oxford handbook of cardiology. 2nd edn. Oxford: Oxford University Press; 2012.

52. Ikorel (nicorandil) 10mg and 20mg tablets. Summary of product characteristics. Marketing authorisation holder: Sanofi-Aventis. Date of first authorisation / renewal of authorisation: 24 February 2009. Date of (partial) revision of text: 15 April 2011. Available at: http://products.sanofi.co.uk/Ikorel­_SPC.pdf. Accessed: 09/30/2020.

53. IONA Study Group. Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management. Heart 2001; 85(6): E9. doi: 10.1136/heart.85.6.e9.

54. European Medicines Agency. Ikorel and Dancor (INN of the active substance: nicorandil). Assessment report. First published: 30/06/2015. Available at: https://www.ema.europa.eu/en/documents/referral/ikorel-dancor-article-30-referral-assessment-report­_en.pdf. Accessed: 09/30/2020.

55. European Medicines Agency. Ikorel and Dancor (INN of the active substance: nicorandil). Assessment report. First published: 30/06/2015. Available at: https://www.ema.europa.eu/en/documents/referral/ikorel-dancor-article-30-referral-assessment-report­_en.pdf. Accessed: 09/30/2020.

56. Pisano U., Deosaran J., Leslie S.J., Rushworth G.F., Stewart D., Ford I., et al. Nicorandil, gastrointestinal adverse drug reactions and ulcerations: a systematic review. Adv Ther 2016; 33(3): 320-344. doi: 10.1007/s12325-016-0294-9.

57. Lupanov V.P. Primenenie nikorandila – aktivatora kalievyh kanalov – v lechenii bol'nyh s ishemicheskoj bolezn'ju serdca [The use of nicorandil – an activator of potassium channels – in the treatment of patients with ischemic heart disease]. Spravochnik poliklinicheskogo vracha [Directory of Polyclinic Doctor] 2011; (8): 44-48. (In Russ).

58. Petrova E.D., Platonova M.D., Bel'diev S.N., Egorova I.V. Opisanie ul'cerogennyh effektov nikorandila v evropejskoj i otechestvennoj instrukcijah po medicinskomu primeneniju preparata [Description of nicorandil-induced ulceration in European and Russian instructions for the medical use of the drug]. Molodezh' i medicinskaja nauka: stat'i VI Vserossijskoj mezhvuzovskoj nauchno-prakticheskoj konferencii molodyh uchenyh s mezhdunarodnym uchastiem (Tver', 22 sentjabrja 2018 g.) [Youth and medical science: articles of VI Russian inter-university scientific and practical conference of young scientists with international participation (Tver, September 22, 2018)]. Tver', 2019. P. 314-317. (In Russ.).

59. Gosudarstvennyj reestr lekarstvennyh sredstv. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Kordinik (nikorandil). Data pereoformlenija registracionnogo udostoverenija – 29.11.2019 [State Register of Medicines (Russian Federation). Instructions for medical use of the drug Kordinik (nicorandil). Date of registration certificate renewal – 11/29/2019]. Available at: https://grls.rosminzdrav.ru/GRLS.aspx. Accessed: 09/30/2020. (In Russ.).

60. Gosudarstvennyj reestr lekarstvennyh sredstv. Instrukcija po medicinskomu primeneniju lekarstvennogo preparata Korevinte (nikorandil). Data gosudarstvennoj registracii – 08.08.2019 [State Register of Medicines (Russian Federation). Instructions for medical use of the drug Korevinte (nicorandil). Date of state registration – 08/08/2019]. Available at: https://grls.rosminzdrav.ru/GRLS.aspx. Accessed: 09/30/2020. (In Russ.).

61. Frampton J., Buckley M.M., Fitton A. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992; 44(4): 625-655. doi: 10.2165/00003495-199244040-00008.

62. Yamamoto K., Matsusue Y., Horita S., Minamiguchi M., Komatsu Y., Kirita T. Nicorandil-induced oral ulceration: report of 3 cases and review of the Japanese literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112(6): 754-759. doi: 10.1016/j.tripleo.2011.05.031.